Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

5/13/24 5:04:15 PM ET

$ELDN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELDN alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Eledon Pharmaceuticals, Inc. [ ELDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.001 par value⁽¹⁾	05/09/2024		P		1,031,385⁽²⁾⁽³⁾	A	⁽²⁾⁽³⁾	3,361,803	D⁽⁵⁾
Common Stock, $0.001 par value⁽¹⁾	05/09/2024		P		821,121⁽²⁾⁽³⁾	A	⁽²⁾⁽³⁾	2,633,679	D⁽⁶⁾
Common Stock, $0.001 par value⁽¹⁾	05/09/2024		P		75,431⁽²⁾⁽³⁾	A	⁽²⁾⁽³⁾	220,460	D⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001	05/09/2024		P		3,173,135		⁽²⁾⁽⁴⁾	⁽²⁾⁽⁴⁾	Common Stock, $0.001 par value	3,173,135	⁽²⁾⁽⁴⁾	3,173,135	D⁽⁵⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001	05/09/2024		P		2,526,238		⁽²⁾⁽⁴⁾	⁽²⁾⁽⁴⁾	Common Stock, $0.001 par value	2,526,238	⁽²⁾⁽⁴⁾	2,526,238	D⁽⁶⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001	05/09/2024		P		232,068		⁽²⁾⁽⁴⁾	⁽²⁾⁽⁴⁾	Common Stock, $0.001 par value	232,068	⁽²⁾⁽⁴⁾	232,068	D⁽⁷⁾
Series X Convertible Preferred⁽¹⁾	⁽⁸⁾							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.001 par value	122,833⁽¹⁰⁾		2,211	D⁽⁵⁾
Series X Convertible Preferred⁽¹⁾	⁽⁸⁾							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.001 par value	96,611⁽¹⁰⁾		1,739	D⁽⁶⁾
Series X Convertible Preferred⁽¹⁾	⁽⁸⁾							⁽⁸⁾	⁽⁸⁾	Common Stock, $0.001 par value	19,222⁽¹⁰⁾		346	D⁽⁷⁾
Series X1 Convertible Preferred⁽¹⁾	⁽⁹⁾							⁽⁹⁾	⁽⁹⁾	Common Stock, $0.001 par value	3,214,437⁽¹⁰⁾		57,860	D⁽⁵⁾
Series X1 Convertible Preferred⁽¹⁾	⁽⁹⁾							⁽⁹⁾	⁽⁹⁾	Common Stock, $0.001 par value	2,374,987⁽¹⁰⁾		42,750	D⁽⁶⁾
Series X1 Convertible Preferred⁽¹⁾	⁽⁹⁾							⁽⁹⁾	⁽⁹⁾	Common Stock, $0.001 par value	424,169⁽¹⁰⁾		7,635	D⁽⁷⁾
Warrants to Purchase Common Stock⁽¹⁾	$12.96⁽¹⁰⁾							⁽¹¹⁾	07/14/2025	Common Stock, $0.001 par value	79,500⁽¹⁰⁾		79,500⁽¹⁰⁾	D⁽⁵⁾
Warrants to Purchase Common Stock⁽¹⁾	$12.96⁽¹⁰⁾							⁽¹¹⁾	07/14/2025	Common Stock, $0.001 par value	64,549⁽¹⁰⁾		64,549⁽¹⁰⁾	D⁽⁶⁾
Warrants to Purchase Common Stock⁽¹⁾	$12.96⁽¹⁰⁾							⁽¹¹⁾	07/14/2025	Common Stock, $0.001 par value	11,415⁽¹⁰⁾		11,415⁽¹⁰⁾	D⁽⁷⁾
Warrants to Purchase Series X1 Convertible Preferred Stock⁽¹⁾	$8,962.74⁽¹⁰⁾							⁽¹²⁾	09/14/2025	Series X1 Convertible Preferred Stock, $0.001 par value	1,453,000⁽¹⁰⁾		1,453	D⁽⁵⁾
Warrants to Purchase Series X1 Convertible Preferred Stock⁽¹⁾	$8,962.74⁽¹⁰⁾							⁽¹²⁾	09/14/2025	Series X1 Convertible Preferred Stock, $0.001 par value	1,086,000⁽¹⁰⁾		1,086	D⁽⁶⁾
Warrants to Purchase Series X1 Convertible Preferred Stock⁽¹⁾	$8,962.74⁽¹⁰⁾							⁽¹²⁾	09/14/2025	Series X1 Convertible Preferred Stock, $0.001 par value	189,000⁽¹⁰⁾		189	D⁽⁷⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹³⁾	12/31/2030	Common Stock, $0.001 par value	254,666		254,666	D⁽⁵⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹³⁾	12/31/2030	Common Stock, $0.001 par value	200,245		200,245	D⁽⁶⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹³⁾	12/31/2030	Common Stock, $0.001 par value	39,938		39,938	D⁽⁷⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹⁴⁾⁽¹⁵⁾	⁽¹⁴⁾⁽¹⁵⁾	Common Stock, $0.001 par value	2,028,645		2,028,645	D⁽⁵⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹⁴⁾⁽¹⁵⁾	⁽¹⁴⁾⁽¹⁵⁾	Common Stock, $0.001 par value	1,609,063		1,609,063	D⁽⁶⁾
Pre-funded Warrants to Purchase Common Stock⁽¹⁾	$0.001							⁽¹⁴⁾⁽¹⁵⁾	⁽¹⁴⁾⁽¹⁵⁾	Common Stock, $0.001 par value	165,950		165,950	D⁽⁷⁾
Warrants to Purchase Common Stock⁽¹⁾	$3							⁽¹⁴⁾⁽¹⁶⁾	⁽¹⁴⁾⁽¹⁶⁾	Common Stock, $0.001 par value	3,084,090		3,084,090	D⁽⁵⁾
Warrants to Purchase Common Stock⁽¹⁾	$3							⁽¹⁴⁾⁽¹⁶⁾	⁽¹⁴⁾⁽¹⁶⁾	Common Stock, $0.001 par value	2,446,209		2,446,209	D⁽⁶⁾
Warrants to Purchase Common Stock⁽¹⁾	$3							⁽¹⁴⁾⁽¹⁶⁾	⁽¹⁴⁾⁽¹⁶⁾	Common Stock, $0.001 par value	252,291		252,291	D⁽⁷⁾

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND L P

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF I GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND II LP

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF II GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

Biotechnology Value Trading Fund OS LP

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF Partners OS Ltd.

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF GP HOLDINGS LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BVF INC/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

LAMPERT MARK N

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FL

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

2. Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the "2024 Purchasers"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the "2024 Private Placement") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the "2024 Pre-Funded Warrants") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share.

3. Shares of Common Stock purchased in the 2024 Private Placement.

4. 2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions.

5. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

6. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

7. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

8. The Series X Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 9.99% of the shares of Common Stock outstanding immediately after giving effect to such exercise. Each share of Series X Convertible Preferred Stock is convertible into 55.55 shares of Common Stock. The Series X Convertible Preferred Stock does not have an expiration date and is subject to certain adjustments pursuant to the Series X Exchange Agreement filed as Exhibit 10.1 to Form 8-K filed by the Issuer with the Securities and Exchange Commission on January 7, 2021.

9. The Series X1 Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 9.99% of the shares of Common Stock outstanding immediately after giving effect to such exercise. Each share of Series X1 Convertible Preferred Stock is convertible into 55.55 shares of Common Stock. The Series X1 Convertible Preferred Stock does not have an expiration date and is subject to certain adjustments pursuant to the Series X1 Exchange Agreement filed as Exhibit 10.1 to Form 8-K filed by the Issuer with the Securities and Exchange Commission on January 13, 2022.

10. Reflects a one-for-eighteen reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of October 5, 2020 (the "Stock Split").

11. Pursuant to a warrant exercise agreement between the Issuer and the Reporting Persons, the Issuer issued to the Reporting Persons warrants to purchase shares of Common Stock at an exercise price of $0.72 per share, with an exercise period of five and a half years (July 14, 2025). The warrants are subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting the Common Stock. The warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with the Exchange Act, more than 9.99% of Common Stock, subject to certain exceptions. In connection with the Stock Split, the exercise price was adjusted to $12.96.

12. Pursuant to a purchase agreement between the Issuer and the Reporting Persons, the Issuer issued to the Reporting Persons warrants to purchase shares of the Series X1 Convertible Preferred Stock at an exercise price of $497.93 per share, with an exercise period of five years (September 14, 2025). Each warrant to purchase shares of the Series X1 Convertible Preferred Stock is convertible into 1 share of Series X1 Convertible Preferred Stock, which is convertible into 1,000 shares of Common Stock. The warrants are subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting the Common Stock. The warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of Common Stock, subject to certain exceptions. In connection with the Stock Split, the exercise price was adjusted to $8,962.74.

13. Pursuant to a warrant exchange agreement between the Issuer and the Reporting Persons, the Issuer issued to the Reporting Persons warrants to purchase shares of Common Stock at an exercise price equal to $0.001 per share, with an exercise period of ten years (December 31, 2030). Each warrant to purchase shares of the Common Stock is convertible into 1 share of Common Stock. The warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of Common Stock, subject to certain exceptions.

14. Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the "2023 Purchasers"), the Issuer agreed to issue and sell to the 2023 Purchasers in a private placement (the "2023 Private Placement"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the "2023 Pre-Funded Warrants"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the "Common Warrants") at a per share purchase price equal to $2.31 (less $0.001 for each 2023 Pre-Funded Warrant, as applicable).

15. 2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions.

16. Common Warrants purchased in the 2023 Private Placement. The Common Warrants are exercisable immediately and have a term of exercise equal to five years. The Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions.

	BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/13/2024
	Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/13/2024
	Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	05/13/2024
	BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	05/13/2024
	BVF Inc., By: /s/ Mark N. Lampert, President	05/13/2024
	/s/ Mark N. Lampert	05/13/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ELDN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELDN

Date	Price Target	Rating	Analyst
1/28/2025	$9.00	Buy	Guggenheim
5/13/2022	$25.00 → $15.00	Overweight	Cantor Fitzgerald
11/24/2021	$35.00 → $25.00	Buy	HC Wainwright & Co.

More analyst ratings

$ELDN
Press Releases

Fastest customizable press release news feed in the world

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025 Proceeds from oversubscribed $85 million underwritten offering extend cash runway to end of 2026 IRVINE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- El
3/20/25 4:01:00 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the managem
3/4/25 4:05:00 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L) with potential to improve both safety and efficacy compared to standard of care immunosuppression regimens IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that tegoprubart, the company's investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a transplanted kidney from a genetically modified pig. The procedure was perfo
2/7/25 10:00:00 AM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

$ELDN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Eledon Pharmaceuticals with a new price target
Guggenheim initiated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00
1/28/25 7:12:35 AM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target
Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously
5/13/22 9:03:12 AM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. reiterated coverage on Eledon Pharmaceuticals with a new price target
HC Wainwright & Co. reiterated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $35.00 previously
11/24/21 6:14:26 AM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

$ELDN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
5/13/24 5:04:15 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

$ELDN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Executive Officer Gros David-Alexandre C
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
1/13/25 5:30:09 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 4 filed by Director Kirk Allan
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
1/13/25 5:30:03 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 4 filed by President Perrin Steven
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
1/13/25 5:30:06 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

$ELDN
SEC Filings

SEC Form 10-K filed by Eledon Pharmaceuticals Inc.
10-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
3/20/25 5:00:30 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
3/20/25 4:05:09 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
12/20/24 8:00:08 AM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

$ELDN
Leadership Updates

Live Leadership Updates

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera
3/28/24 4:01:00 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i
1/4/24 4:40:44 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno
11/9/23 4:01:00 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

$ELDN
Financials

Live finance-specific insights

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation Eledon will host a conference call today at 5:00 p.m. ET IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results
11/2/23 9:05:00 AM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed financing of up to $185 million, with $35 million upfront, to fund the Company through the Phase 2 BESTOW kidney transplant trial, subject to achieving specific milestones Conference call today at 4:30 p.m. ET IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter operating and financial results and reviewed recent business highlights. "Eledon made significant progress this year in advancing the clinical developmen
5/11/23 4:01:00 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it plans to release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details: Thursday, May 11, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific TimeToll Free: 888-886-7786International: 416-764-8658Conference ID: 11107025Webcast: https://ir.eledon.com/events-and-presentations/events After the live webcast, the event will be archived on Eledon's website for one year. About Eledon Phar
5/4/23 4:05:00 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

$ELDN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Eledon Pharmaceuticals Inc.
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
11/14/24 4:51:31 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
11/5/24 4:17:26 PM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form SC 13G filed by Eledon Pharmaceuticals Inc.
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
11/5/24 11:44:57 AM ET
$ELDN
Biotechnology: Pharmaceutical Preparations
Health Care

Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

Chat with this insight

Recent Analyst Ratings for $ELDN

$ELDN Press Releases

Fastest customizable press release news feed in the world

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

$ELDN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Eledon Pharmaceuticals with a new price target

Cantor Fitzgerald resumed coverage on Eledon Pharmaceuticals with a new price target

HC Wainwright & Co. reiterated coverage on Eledon Pharmaceuticals with a new price target

$ELDN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.